ST Pharm: revenue up 19.1%, net income falls on FX losses
According to TradingView, ST Pharm's third-quarter revenue rose 19.1% while net income dropped to KRW 0.9bn, mainly due to currency losses.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, South Korea's ST Pharm posted third-quarter revenue up 19.1% year on year, reaching KRW 97.6bn. Operating profit grew 6.6%. Net income, however, fell to KRW 0.9bn, mainly because of foreign exchange losses.
The company reported growth in commercial oligonucleotide sales. It also expects further margin improvement in its Small Molecule business.
why it matters
For investors, the key point is the gap between operating growth and net income: currency effects offset the benefit of higher revenue. Margin trends in Small Molecule and oligonucleotide sales remain the main drivers, so the FX factor deserves attention when reading the company's results.
tags
instruments
sources
- ST Pharm: Revenue growth and higher operating profit were offset by FX-driven net income decline — TradingView, 27 October 2026 at 02:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗